Market News
Smart Trading. Simplified.
A Rare Opportunity to Turn $1,000 into $461,800
On August 30, 2019, a small firm won a contract from the Pentagon to build a strange new weapon. The Joint Chiefs of Staff calls this new weapon "Unstoppable." This under-the-radar company is not yet a household name.
Our research proves that anyone who gets in now could turn $1,000 into $461,800 >>>
Is Pinterest Stock Overvalued?
Pinterest stock has been rallying since mid-May, growing 35% off of lows not seen since the end of last year. The company suffered a precipitous drop in its share price in April after the market moved against the business in the wake of what was actually a pretty good first quarter 2021 earnings report. However, […]
Small Biotech Could Soar 1,000%
There's no sector poised to deliver bigger gains in 2021 than small-cap biotech stocks.
In the past year alone...
Novavax Inc jumped from $6.26 to $270.51, a gain of 3,396%.
Aclaris Therapts jumped from $0.70 to $24.28 an increase of 1,583%.
Vaxart Inc rocketed from $0.97 to $14.94, a 1,083% jump.
Here's the next biotech we think could soar 1,000% >>>
Is fuboTV Stock Overvalued?
As more and more people join the already countless number of individuals who have cut cable in recent years in favor of much more affordable and convenient streaming services, it only makes sense to see those streaming services become more valuable as a result. This is especially true of those streamers that can provide users […]
New Investing eBook - Ultimate Guide to Real Estate Stocks.
Expand your portfolio by adding Real Estate Stocks and REITs that have outperformed the S&P 500 since the 1970s. Learn about these overlooked stocks and add high performance and stability to your portfolio.
Why Is IDEXX Going Up?
IDEXX has been building reliable veterinary devices since 1983. Recently, the company acquired ezyVet, a company that provides cloud software and information-management systems for veterinarians. Many investors believe that the acquisition signals a new era in veterinary medicine and could help establish IDEXX Laboratories as a leading provider of cutting-edge services. What Does IDEXX Laboratories […]
Is this Killer new EXTRA INCOME strategy the Best Side Hustle EVER?
Have you seen this new extra-income hack yet?
Everyday Americans have been making 100%, 200%, 500%, or more... sometimes in a matter of days with this one new strategy. Some of them are retiring from their jobs because of it. Others have paid off all their debt and bought their dream homes.
You can see their stories for yourself right here.
dlocal Stock Price Prediction
Smart investors have their eyes on two specific opportunities – two areas that are expected to grow rapidly, both short-term and long-term. The first is digital payment solutions. The use of cash has experienced a gradual decline as e-commerce transactions ramp up, and every one of those transactions requires a source of electronic payment. That’s […]
The World's First $20 Trillion Drug?
One small biotech holds the key to a revolution in treating Alzheimer's. Jeff Bezos, Goldman Sachs & a Big Pharma giant have invested billions into this unknown biotech.
Our research shows that anyone who gets in by August 6th, 2021 could turn every $1,000 into $1.1 million.
Will Alibaba Stock Go Up After Earnings?
Alibaba Group Holding Limited, also referred to as the Alibaba Group or simply Alibaba.com, is slated to release their next earnings report on August 3rd. The multinational technology company that is best known for specializing in things like e-commerce, internet, retail, and even film production has seen its stock on a steady decline for almost […]
How To Use Technical Indicators (The Right Way)
Predictive analysis is revolutionizing the trading space as we know it. With high-accuracy forecasting, traders can dodge losses and squeeze the most out of gains.
Our experts want to empower you with the knowledge and education to trade intelligently. Check out today's deep dive into cutting-edge, predictive technical indicators to see the tricks and tips you may not know about.
Click here to register for free.
View this email online if it doesn't display correctly. This newsletter is not financial advice. Please read our Disclaimer.
To unsubscribe from Financhill, click here.
PO Box 126
Catasauqua, PA 18032
Financhill is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of Financhill are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.
The sender of this email makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity's compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.
The content on any of Financhill websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The Financhill.com educational training program and software services are provided to improve financial understanding.
The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.
Past performance is no guarantee of future performance. This product is for educational purposes only. Practical application of the products herein are at your own risk and Financhill.com, its partners, representatives and employees assume no responsibility or liability for any use or mis-use of the product. Please contact your financial advisor for specific financial advice tailored to your personal circumstances. Any trades shown are hypothetical example and do not represent actual trades. Actual results may differ. Nothing here in constitutes a recommendation respecting the particular security illustrated.
No comments:
Post a Comment